Название продукции:2,3-Difluoropyridine
IUPAC Name:2,3-difluoropyridine
- CAS:1513-66-2
- Молекулярная формула:C5H3F2N
- Чистота:98%
- Номер в каталоге:CM120583
- Молекулярная масса:115.08
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:1513-66-2
- Молекулярная формула:C5H3F2N
- Точка плавления:-
- Smiles-код:FC1=CC=CN=C1F
- Плотность:
- Номер в каталоге:CM120583
- Молекулярная масса:115.08
- Точка кипения:
- Номер Mdl:MFCD04114143
- Хранение:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- NST-628
- Nested Therapeutics’ lead program, NST-628, is an oral, brain-penetrant pan-RAF-MEK non-degrading molecular glue that lacks paradoxical pathway activation through the prevention of RAF paralog heterodimerization. By inhibiting the phosphorylation and activation of MEK by RAF, NST-628 targets a critical step in the RAS/RAF/MAPK signaling pathway. Preclinically, NST-628 results in broad efficacy, high tolerability, CNS activity across various RAS- and RAF-driven tumor models, and has the potential to deliver transformative clinical benefits both as a monotherapy and as a key component in combination therapies. Now, NST-628 has advanced to a Ph. I trial in patients with refractory MAPK pathway mutated/dependent advanced solid tumors.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.